We thank Hofstetter and colleagues  for their interest in the position paper we published in the Journal of Hypertension on behalf of the European Society of Hypertension . We agree with their point that there is no obvious reason why among the 15 polypills under development, the vast majority, that is 13, include an angiotensin-converting enzyme inhibitor (ACEI) and only two assign to an AT1 blockers (ARB) the blood pressure (BP) lowering component of a polypill. This is because meta-analyses of randomized trials comparing ACEIs and ARBs have not shown cardiovascular morbidity and mortality to differ significantly between these treatments . It is also because cost is now no more a major factor in the choice, given that not only ACEIs but also ARBs are available in generic form. It is finally because, as Hofstetter et al. correctly emphasize, ARB have the best tolerability profile among available antihypertensive drug classes. As side effects are the major cause of treatment discontinuation , this accounts for the evidence that discontinuation is less with ARB than with ACEI treatment, a clinically relevant phenomenon because treatment discontinuation leads to a substantial increase of cardiovascular risk and mortality .